EUVIMEDEUVIMED entdecken
Crossref

Population Pharmacokinetic Analysis of Dolutegravir in Treatment‐Experienced Adults Living with HIV‐1

Hardik Chandasana iD, Mark Bush, Mounir Ait-Khaled, Brian Wynne, Sherene Min, Rashmi Mehta

The Journal of Clinical Pharmacology · 2024

DOI: 10.1002/jcph.2494 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Pharmacology, 2024. Verfasst von Hardik Chandasana und 5 weiteren Autor:innen. Beteiligte Einrichtung: GSK, Collegeville, PA, USA. Hauptthemen laut MEDLINE: Heterocyclic Compounds, 3-Ring, Oxazines, Pyridones, Piperazines. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 33 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The World Health Organization has recommended the use of dolutegravir (DTG) for both first and second‐line antiretroviral treatment in both adults and children down to 4 weeks of age. We developed a population pharmacokinetic(PopPK) model following oral administration of DTG 50 mg QD and 50 mg BID in HIV‐infected treatment‐experienced adults (607) based on pooled data from four phase 2/3 trials. DTG population pharmacokinetics are described by a one‐compartment model with first‐order absorption, absorption lag‐time, and first‐order elimination. The PopPK parameter estimates were apparent oral clearance (CL/F) = 1.00 L/h, apparent volume of distribution (V/F) = 18.9 L, absorption rate constant (Ka) = 1.99 per hour, and absorption lag time = 0.333 h, respectively. The final model included inter‐individual and inter‐occasion variability on apparent clearance (CL/F). Weight, smoking status, use of metabolic inducers as part of background antiretroviral therapy (ART) classified by their level of induction, use of atazanavir or atazanavir‐ritonavir as part of background ART, and albumin level were predictors of CL/F; weight and albumin level were predictors of V/F; and sex and concomitant use of metal cation‐containing vitamin/mineral supplements were predictors of relative bioavailability (F). The current model‐based analysis suggests that the DTG dose adjustment is not required based on the demographics, laboratory values, smoking status, concomitant use of mild metabolic inducers or inhibitors in the background therapy, or use of metal cation‐containing vitamin/mineral supplements because these covariate effects are not predicted to have a clinically relevant impact on safety and efficacy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heterocyclic Compounds, 3-RingOxazinesPyridonesPiperazinesHIV InfectionsHIV-1Models, BiologicalHumansMaleFemaleAdultMiddle AgedHIV Integrase InhibitorsYoung AdultAdolescentAgedDolutegravir

Stichwörter der Autor:innen

dolutegravirintegrase inhibitorpopulation pharmacokineticstreatment‐experienced

Substanzen

Heterocyclic Compounds, 3-RingOxazinesPyridonesPiperazinesHIV Integrase InhibitorsDolutegravir

Autor:innen und Institutionen

  • GSK, Collegeville, PA, USA.
  • ViiV Healthcare, Durham, NC, USA.
  • ViiV Healthcare Ltd, Brentford, UK.
  • GSK, Durham, NC, USA.

ORCID-Profile: Hardik Chandasana

Zitieren

APA

Chandasana, H., Bush, M., Ait-Khaled, M., Wynne, B., Min, S., & Mehta, R. (2024). Population Pharmacokinetic Analysis of Dolutegravir in Treatment‐Experienced Adults Living with HIV‐1. The Journal of Clinical Pharmacology. https://doi.org/10.1002/jcph.2494

Vancouver

Chandasana H, Bush M, Ait-Khaled M, Wynne B, Min S, Mehta R. Population Pharmacokinetic Analysis of Dolutegravir in Treatment‐Experienced Adults Living with HIV‐1. The Journal of Clinical Pharmacology. 2024. doi:10.1002/jcph.2494

BibTeX
@article{Chandasana2024,
  author = {Chandasana, Hardik and Bush, Mark and Ait-Khaled, Mounir and Wynne, Brian and Min, Sherene and Mehta, Rashmi},
  title = {Population Pharmacokinetic Analysis of Dolutegravir in Treatment‐Experienced Adults Living with HIV‐1},
  journal = {The Journal of Clinical Pharmacology},
  year = {2024},
  doi = {10.1002/jcph.2494}
}
Kostenlos starten →